# Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

> **NCT04676724** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 108 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** GSK3228836
- **DRUG:** PegIFN
- **DRUG:** NA therapy

## Key facts

- **NCT ID:** NCT04676724
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-28
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-17
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676724, "Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04676724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*